Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
8.61
USD
Market Cap:
$391.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
US |
|
Xcel Energy Inc
NASDAQ:XEL
|
US |
|
Pierce Group AB (publ)
STO:PIERCE
|
SE |
|
Lululemon Athletica Inc
NASDAQ:LULU
|
CA |
|
C
|
Capstone Green Energy Corp
F:TBN2
|
US |
|
L
|
Lancer Container Lines Ltd
NSE:LANCER
|
IN |
|
Star Energy Group PLC
LSE:STAR
|
UK |
|
Chesapeake Energy Corp
NASDAQ:CHK
|
US |
|
APAQ Technology Co Ltd
TWSE:6449
|
TW |
|
B
|
Blender Financial Technologies Ltd
TASE:BLND
|
IL |
|
W
|
Wuxi Boton Technology Ltd
SZSE:300031
|
CN |
|
Unicharm Corp
TSE:8113
|
JP |
|
A
|
Anemoi International Ltd
LSE:AMOI
|
VG |
|
ETHZilla Corp
NASDAQ:ETHZ
|
US |
|
P
|
Puma SE
OTC:PUMSY
|
DE |
|
D
|
Dollarama Inc
OTC:DLMAF
|
CA |
Balance Sheet
Balance Sheet Decomposition
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
Balance Sheet Decomposition is not available for
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
Balance Sheet
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
17
|
91
|
148
|
207
|
115
|
182
|
106
|
79
|
67
|
|
| Cash Equivalents |
17
|
91
|
148
|
207
|
115
|
182
|
106
|
79
|
67
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
8
|
13
|
22
|
20
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
8
|
13
|
22
|
20
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
6
|
7
|
5
|
7
|
|
| Other Current Assets |
0
|
1
|
4
|
5
|
8
|
8
|
6
|
5
|
4
|
|
| Total Current Assets |
17
|
91
|
152
|
212
|
122
|
202
|
130
|
111
|
99
|
|
| PP&E Net |
0
|
0
|
0
|
4
|
6
|
6
|
2
|
2
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
2
|
3
|
3
|
2
|
|
| Other Long-Term Assets |
0
|
1
|
0
|
0
|
3
|
3
|
6
|
12
|
18
|
|
| Total Assets |
17
N/A
|
92
+432%
|
152
+65%
|
216
+42%
|
132
-39%
|
213
+61%
|
142
-34%
|
128
-10%
|
120
-6%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
6
|
6
|
9
|
9
|
14
|
14
|
6
|
7
|
|
| Accrued Liabilities |
1
|
2
|
3
|
5
|
10
|
14
|
14
|
14
|
17
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
3
|
8
|
9
|
14
|
20
|
28
|
28
|
20
|
24
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
2
|
2
|
2
|
4
|
7
|
5
|
4
|
7
|
4
|
|
| Total Liabilities |
5
N/A
|
10
+92%
|
11
+14%
|
18
+54%
|
26
+50%
|
33
+25%
|
32
-2%
|
27
-17%
|
28
+4%
|
|
| Equity | ||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
22
|
42
|
85
|
166
|
285
|
341
|
436
|
457
|
487
|
|
| Additional Paid In Capital |
34
|
124
|
225
|
365
|
392
|
519
|
544
|
558
|
577
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
2
|
|
| Total Equity |
12
N/A
|
82
+579%
|
141
+71%
|
199
+42%
|
106
-47%
|
180
+70%
|
109
-39%
|
101
-8%
|
92
-9%
|
|
| Total Liabilities & Equity |
17
N/A
|
92
+432%
|
152
+65%
|
216
+42%
|
132
-39%
|
213
+61%
|
142
-34%
|
128
-10%
|
120
-6%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
33
|
33
|
34
|
40
|
41
|
44
|
44
|
44
|
45
|
|
Switch to:
Switch to:
See Also
Discover More
